Summary & Overview
HCPCS Q4409: Amniomatrixf3x, Biologic Matrix per cm2
HCPCS Level II code Q4409 represents Amniomatrixf3x billed per square centimeter as an add-on biologic matrix product used to augment tissue coverage during wound care, reconstructive, or surgical procedures. Nationally, add-on biologic matrix codes matter because they affect bundled procedure payments, clinical documentation requirements, and coverage determinations for advanced wound and reconstructive therapies. Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn what Q4409 denotes clinically, how it is positioned as an add-on supply in procedure claims, and which payers commonly adjudicate such codes. The publication summarizes benchmarks and coverage considerations relevant to hospitals and ambulatory surgical centers, highlights where policy updates typically occur for biologic graft materials, and outlines clinical contexts in which per-square-centimeter billing is applied. Information on coding practice, common sites of service, and typical use cases for matrix products is provided to help billing and revenue cycle teams understand claim reporting and payer interactions. Data not available in the input for modifiers, related taxonomies, ICD-10 pairings, and specific payer policy language are noted where applicable.
Billing Code Overview
HCPCS Level II code Q4409 describes Amniomatrixf3x, billed per square centimeter. This item is an add-on biological matrix product intended to be reported in addition to a primary procedure when used to cover or augment tissue. The service type is biologic graft/matrix application, and the typical site of service is outpatient procedure settings such as hospital outpatient departments or ambulatory surgery centers where wound management or reconstructive procedures are performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a chronic or non-healing soft tissue wound (eg, diabetic foot ulcer, venous stasis ulcer, pressure injury, or surgical wound dehiscence) referred to a wound care clinic or outpatient surgical center for advanced biologic grafting. The clinician evaluates wound size, depth, infection status, and vascular supply, then debrides necrotic tissue and achieves hemostasis. Q4409 — an amniotic-derived graft product billed per square centimeter — is applied directly to the prepared wound bed as an adjunctive biologic scaffold to support healing. The product is documented with exact square centimeter amount used, lot number, and application technique. Typical workflow includes wound assessment, cleansing, sharp or enzymatic debridement (if needed), measurement of wound area, application of the Q4409 material to cover the wound, fixation with secondary dressing or negative pressure therapy as indicated, and scheduled follow-up visits for assessment and potential repeat applications. Procedures commonly occur in outpatient wound care clinics, ambulatory surgery centers, or hospital outpatient departments. Patient counseling covers wound care plan, risks, and signs of infection. Documentation includes diagnostic code(s), number of square centimeters applied, and linkage to the primary procedure code(s) billed during the same encounter.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 |